Baader Bank Aktiengesellschaft Viracta Therapeutics, Inc. Transaction History
Baader Bank Aktiengesellschaft
- $1.31 Billion
- Q2 2025
Shares
2 transactions
Others Institutions Holding VIRX
# of Institutions
11Shares Held
467KCall Options Held
0Put Options Held
0-
Black Rock Inc. New York, NY273KShares$2,7320.0% of portfolio
-
Xtx Topco LTD London, X093.4KShares$9330.0% of portfolio
-
United Capital Financial Advisers, LLC Newport Beach, CA43KShares$4290.0% of portfolio
-
Wealth Trust Axiom LLC16.4KShares$1630.0% of portfolio
-
Hoyle Cohen, LLC14KShares$1400.0% of portfolio
About Viracta Therapeutics, Inc.
- Ticker VIRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 37,558,200
- Market Cap $376K
- Description
- Viracta Therapeutics, Inc., a precision oncology company, engages in developing drugs for the treatment of virus-associated malignancies. Its lead product candidature includes Nana-val, in combination with nanatinostat and valganciclovir that is in Phase II clinical trial for Epstein-Barr virus-positive lymphoma; and open-label Phase 2 basket tr...